Evidence map›Paper›PMID 38739587›Full record

ArticlePloS one2024

Synthesis, molecular docking study and biological evaluation of new pyrrole scaffolds as potential antitubercular agents for dual targeting of enoyl ACP reductase and dihydrofolate reductase.

Mater H Mahnashi, Sravanthi Avunoori, Sanjay Gopi, Ibrahim Ahmed Shaikh, Ahmed Saif, Farkad Bantun, Hani Saleh Faidah, Abdulrahman Ali Alhadi, Jaber Hassan Alshehri, Abdullah Ali Alharbi and 2 more

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mater H MahnashiDepartment of Pharmaceutical Chemistry, College of Pharmacy, Najran University, Najran, Saudi Arabia.ORCID 0009-0007-8646-1009
Sravanthi AvunooriDepartment of Pharmaceutical Chemistry, Novel Drug Design and Discovery Laboratory, SET's College of Pharmacy, Sangolli Rayanna Nagar, Dharwad, Karnataka, India.
Sanjay GopiDepartment of Pharmaceutical Chemistry, Novel Drug Design and Discovery Laboratory, SET's College of Pharmacy, Sangolli Rayanna Nagar, Dharwad, Karnataka, India.
Ibrahim Ahmed ShaikhDepartment of Pharmacology, College of Pharmacy, Najran University, Najran, Saudi Arabia.ORCID 0000-0001-9812-2628
Ahmed SaifDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
Farkad BantunFaculty of Medicine, Department of Microbiology, Umm Al-Qura University, Makkah, Saudi Arabia.
Hani Saleh FaidahFaculty of Medicine, Department of Microbiology, Umm Al-Qura University, Holy Makkah, Kingdom of Saudi Arabia.
Abdulrahman Ali AlhadiFaculty of Medicine, Department of Microbiology, Umm Al-Qura University, Holy Makkah, Kingdom of Saudi Arabia.
Jaber Hassan AlshehriMicrobiology Section Pathology and Laboratory Medicine, Armed Forces Hospital Southern Region, Khamis Mushait, Kingdom of Saudi Arabia.
Abdullah Ali AlharbiMicrobiology Section Pathology and Laboratory Medicine, Armed Forces Hospital Southern Region, Khamis Mushait, Kingdom of Saudi Arabia.
Prem Kumar S RDepartment of Pharmaceutical Chemistry, MVM College of Pharmacy, Yelahanka, Bengaluru, Karnataka, India.
Shrinivas D JoshiDepartment of Pharmaceutical Chemistry, Novel Drug Design and Discovery Laboratory, SET's College of Pharmacy, Sangolli Rayanna Nagar, Dharwad, Karnataka, India.ORCID 0000-0002-6520-806X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, new series of N'-(2-(substitutedphenoxy)acetyl)-4-(1H-pyrrol-1-yl)benzohydrazides (3a-j) 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N'-(2-(substitutedphenoxy)acetyl)benzohydrazides (5a-j) were synthesized, characterized and assessed as inhibitors of enoyl ACP reductase and DHFR. Most of the compounds exhibited dual inhibition against the enzymes enoyl ACP reductase and DHFR. Several synthesized substances also demonstrated significant antibacterial and antitubercular properties. A molecular docking analysis was conducted in order to determine the potential mechanism of action of the synthesized compounds. The results indicated that there were binding interactions seen with the active sites of dihydrofolate reductase and enoyl ACP reductase. Additionally, important structural details were identified that play a critical role in sustaining the dual inhibitory activity. These findings were useful for the development of future dual inhibitors. Therefore, this study provided strong evidence that several synthesized molecules could exert their antitubercular properties at the cellular level through multi-target inhibition. By shedding light on the mechanisms through which these compounds exert their inhibitory effects, this research opens up promising avenues for the future development of dual inhibitors with enhanced antibacterial and antitubercular properties. The study's findings underscore the importance of multi-target approaches in drug design, providing a strong foundation for the design and optimization of novel compounds that can effectively target bacterial infections at the cellular level.

Indexed as

Antitubercular AgentsPyrrolesTetrahydrofolate DehydrogenaseCatalytic DomainEnoyl-(Acyl-Carrier-Protein) Reductase (NADH)Folic Acid AntagonistsHumansMicrobial Sensitivity TestsMolecular Docking SimulationMycobacterium tuberculosisStructure-Activity RelationshipAntitubercular AgentsEnoyl-(Acyl-Carrier-Protein) Reductase (NADH)Folic Acid AntagonistsPyrrolesTetrahydrofolate Dehydrogenase

Identifiers

PMID38739587
PMCPMC11090339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.